- Home
- ANVS vs ICCM Comparison
ANVS vs ICCM Comparison
Compare ANVS & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- ICCM
- Stock Information
- Founded
- ANVS 2008
- ICCM 2006
- Country
- ANVS United States
- ICCM Israel
- Employees
- ANVS N/A
- ICCM N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- ICCM
- Sector
- ANVS Health Care
- ICCM
- Exchange
- ANVS Nasdaq
- ICCM Nasdaq
- Market Cap
- ANVS 55.5M
- ICCM 61.1M
- IPO Year
- ANVS 2020
- ICCM N/A
- Fundamental
- Price
- ANVS $2.34
- ICCM $1.05
- Analyst Decision
- ANVS Strong Buy
- ICCM Strong Buy
- Analyst Count
- ANVS 4
- ICCM 1
- Target Price
- ANVS $17.33
- ICCM $2.00
- AVG Volume (30 Days)
- ANVS 231.9K
- ICCM 2.0M
- Earning Date
- ANVS 11-07-2025
- ICCM 08-13-2025
- Dividend Yield
- ANVS N/A
- ICCM N/A
- EPS Growth
- ANVS N/A
- ICCM N/A
- EPS
- ANVS N/A
- ICCM N/A
- Revenue
- ANVS N/A
- ICCM $2,787,000.00
- Revenue This Year
- ANVS N/A
- ICCM $62.11
- Revenue Next Year
- ANVS N/A
- ICCM $142.91
- P/E Ratio
- ANVS N/A
- ICCM N/A
- Revenue Growth
- ANVS N/A
- ICCM N/A
- 52 Week Low
- ANVS $1.11
- ICCM $0.48
- 52 Week High
- ANVS $10.54
- ICCM $1.66
- Technical
- Relative Strength Index (RSI)
- ANVS 43.00
- ICCM 55.55
- Support Level
- ANVS $2.21
- ICCM $1.02
- Resistance Level
- ANVS $2.51
- ICCM $1.12
- Average True Range (ATR)
- ANVS 0.13
- ICCM 0.07
- MACD
- ANVS -0.01
- ICCM 0.01
- Stochastic Oscillator
- ANVS 25.35
- ICCM 44.79
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.